PHAT News and Press, Phathom Pharmaceuticals Inc. From 04/29/21

Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy New Drug Application (NDA) submissions targeted for Q4 2021 Phathom to host conference call and live webcast today, Apri...

Phantom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years. Phantom's drug, vonoprazan, has already succeeded in multiple Phase 3 trials overseas, which should bode well for its two ongoi...

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team ...

Phathom Pharmaceuticals (PHAT): Q4 GAAP EPS of -$1.58 misses by $0.56.Cash and cash equivalents of $287.5M.Press Release For further details see: Phathom Pharmaceuticals EPS misses by $0.56

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quar...

Phathom is attempting to commercialize a treatment for Gastroesophageal Reflux Disease and H. Pylori in the US and Europe that has proven successful in Asia & Latin America. The company has in-licensed rights to Vonoprazan from Takeda. The drug presents numerous advantages to curr...

Phathom Pharmaceuticals (PHAT) has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan and vonoprazan for the eradication of H. pylori infection.PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H...

Topline results expected in second quarter of 2021 NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical ...

The following slide deck was published by Phathom Pharmaceuticals, Inc. in conjunction with this event. For further details see: Phathom Pharmaceuticals (PHAT) Investor Presentation - Slideshow

Gainers: Vivos Therapeutics (VVOS) +51%, Jupiter Wellness (JUPW) +21%, Evolus (EOLS) +27%, PainReform (PRFX) +24%, Rite Aid (RAD) +23%.Losers: BioCardia (BCDA) -23%, SCYNEXIS (SCYX) -19%, Zynerba Pharmaceuticals (ZYNE) -15%, Han...